Free Trial
NASDAQ:BBLG

Bone Biologics Q2 2025 Earnings Results & Report

Bone Biologics logo
$0.47 0.00 (-0.43%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$0.47 +0.00 (+0.62%)
As of 10/9/2026 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Bone Biologics missed analyst earnings expectations in its Q2 2025 results, released August 14, 2025. The company reported EPS of -$1.33 versus the -$0.58 consensus estimate.

Earnings Announcement Details

Quarter
Q2 2025
Report Date
Time
Before Market Opens

Bone Biologics EPS Results

Actual EPS
-$1.33
Consensus EPS
-$0.58
Beat/Miss
Missed by -$0.75
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 8 quarters

Bone Biologics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

Bone Biologics' next earnings date is estimated for Friday, November 13, 2026, based on past reporting schedules.

Conference Call Resources

Bone Biologics Q2 2025 Earnings FAQ

Bone Biologics (NASDAQ:BBLG) reported earnings of -$1.33 per share for Q2 2025, missing the consensus estimate of -$0.58. The report was announced on Thursday, August 14, 2025.

Bone Biologics' next earnings date is estimated for Friday, November 13, 2026. MarketBeat tracks confirmed and estimated earnings dates for Bone Biologics on the company's earnings history page.

Bone Biologics Earnings Headlines

Bone Biologics Expands Trial Sites
This free guide explains options the way they should be taught
Most options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before they ever place a trade. This free guide from Base Camp Trading takes a different approach, starting with the basics and showing you exactly how options work, why traders use them, and how they fit into a simple trading plan.tc pixel
BBLG Efficiency Improves as Crucial Trials Advance
See More Bone Biologics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bone Biologics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bone Biologics and other key companies, straight to your email.

About Bone Biologics

Bone Biologics (NASDAQ:BBLG) Corporation (NASDAQ: BBLG) is a biotechnology company focused on developing regenerative medicine products for the orthopedic and spine markets. Its work centers on bone growth and spinal fusion, where physicians use biologic materials and implants to help stabilize the spine and support the formation of new bone.

The company’s primary technology is based on NELL-1, a recombinant human protein that has demonstrated bone-forming properties in preclinical and clinical research. Bone Biologics has been developing NELL-1-based products, including bone graft substitutes intended for use with spinal fusion procedures. The company’s strategy is to combine its biologic technology with established scaffold materials and delivery systems to create products designed to promote bone regeneration.

Bone Biologics has historically operated as a development-stage biotechnology company and has focused its research and commercialization efforts primarily on the United States spine and orthopedic markets. Its products remain subject to clinical development and regulatory approval, and the company has not established a broad portfolio of commercially marketed products based on the available information.

View Bone Biologics Profile